Premium
Relationship between PASI and FDLQI in paediatric psoriasis, and treatments used in daily clinical practice
Author(s) -
Kim Emma,
Fischer Gayle
Publication year - 2021
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.13536
Subject(s) - medicine , psoriasis , psoriasis area and severity index , dermatology life quality index , quality of life (healthcare) , severity of illness , adverse effect , disease , outpatient clinic , clinical practice , dermatology , pediatrics , physical therapy , nursing
Background/Objectives Psoriasis is a chronic, inflammatory skin disease that affects 0.71% of children. Skin diseases can have a significant impact on quality of life not only for the children affected by psoriasis, but also for their parents and carers. This study aimed to achieve more insight into the quality of life (QOL) of family of paediatric patients with psoriasis, and to investigate whether disease severity scores correlate with Family Dermatology Life Quality Index (FDLQI) scores. In addition, we also observed the treatments used to treat paediatric psoriasis in daily clinical practice. Methods Patients with paediatric psoriasis aged 16 and under who visited our outpatient department were included. Baseline Psoriasis Area and Severity Index (PASI) and FDLQI were measured and analysed. Results Of 157 patients were included in the study. Median PASI was 4.2 (IQR 2.6–6.9), and the median FDLQI was 12 (IQR 7–17). The correlation coefficient between PASI and FDLQI was 0.44 ( P < 0.001). Burden of care was the highest scoring item on the FDLQI, followed by emotional impact. 146 patients were treated with topical therapy with a mean improvement in PASI of 3.92. 19 patients underwent phototherapy, and 19 underwent systemic therapy. Conclusions In this largest study to date studying the impact of PASI on FDLQI, disease severity was found to be strongly associated with adverse quality of life of family members of paediatric psoriasis patients.